Interfuranylene prostacyclins
US4740523A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 17, 1986 |
| Grant date | Apr 26, 1988 |
| Priority date | — |
| Expiry date | Jan 17, 2006 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to novel interfuranylene-prostacyclin derivatives of the general formula (I) ##STR1## wherein R.sup.1 stands for hydrogen or a straight or branched chain C.sub.1-6 alkyl group, an inorganic cation or for the protonated form of a base containing an amino group; PA0 R.sup.2 stands for hydrogen, a C.sub.1-4 alkanoyl or benzoyl group, a monosubstituted benzoyl, trialkylsilyl or an alkoxyalkyl group; PA0 R.sup.3 stands for a straight or branched chain C.sub.1-6 alkyl group, a phenyl group optionally substituted by halogen or by a C.sub.1-4 alkyl group, a heteroaryl group optionally substituted by halogen or by a C.sub.1-4 alkyl group or a cycloalkyl group; PA0 A stands for an ethylene or for a cis- or trans-vinylene or --C.tbd.C-- group; PA0 B means a chemical bond, a --CHR.sup.5 --, --CHR.sup.5 --CH.sub.2 -- or a --CH.sub.2 --O-- group: and PA0 R.sup.5 means hydrogen or a C.sub.1-4 alkyl group. The compounds of the formula (I) can be used therapeutically as platelet aggregation inhibiting, anti-thrombotic, hypotensive and anti-antherosclerotic agents; they are much more stable than the natural prostacyclin derivatives.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.